These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35234630)

  • 1. Cryo-EM structure of glycoprotein C from Crimean-Congo hemorrhagic fever virus.
    Li N; Rao G; Li Z; Yin J; Chong T; Tian K; Fu Y; Cao S
    Virol Sin; 2022 Feb; 37(1):127-137. PubMed ID: 35234630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing monoclonal antibodies against the Gc fusion loop region of Crimean-Congo hemorrhagic fever virus.
    Li L; Chong T; Peng L; Liu Y; Rao G; Fu Y; Shu Y; Shen J; Xiao Q; Liu J; Li J; Deng F; Yan B; Hu Z; Cao S; Wang M
    PLoS Pathog; 2024 Feb; 20(2):e1011948. PubMed ID: 38300972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fine mapping epitope on glycoprotein Gc from Crimean-Congo hemorrhagic fever virus.
    Zhang J; Simayi A; Wang M; Moming A; Xu W; Wang C; Li Y; Ding J; Deng F; Zhang Y; Sun S
    Comp Immunol Microbiol Infect Dis; 2019 Dec; 67():101371. PubMed ID: 31627038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.
    Zivcec M; Guerrero LIW; Albariño CG; Bergeron É; Nichol ST; Spiropoulou CF
    Antiviral Res; 2017 Oct; 146():112-120. PubMed ID: 28842265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38.
    Mishra AK; Moyer CL; Abelson DM; Deer DJ; El Omari K; Duman R; Lobel L; Lutwama JJ; Dye JM; Wagner A; Chandran K; Cross RW; Geisbert TW; Zeitlin L; Bornholdt ZA; McLellan JS
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31996434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
    Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A
    J Virol; 2017 May; 91(10):. PubMed ID: 28250124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and evaluation of DNA vaccine encoding Crimean Congo hemorrhagic fever virus nucleocapsid protein, glycoprotein N-terminal and C-terminal fused with LAMP1.
    Hu YL; Zhang LQ; Liu XQ; Ye W; Zhao YX; Zhang L; Qiang ZX; Zhang LX; Lei YF; Jiang DB; Cheng LF; Zhang FL
    Front Cell Infect Microbiol; 2023; 13():1121163. PubMed ID: 37026060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleoside-Modified mRNA Vaccines Protect IFNAR
    Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A
    J Virol; 2022 Feb; 96(3):e0156821. PubMed ID: 34817199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever.
    Fels JM; Maurer DP; Herbert AS; Wirchnianski AS; Vergnolle O; Cross RW; Abelson DM; Moyer CL; Mishra AK; Aguilan JT; Kuehne AI; Pauli NT; Bakken RR; Nyakatura EK; Hellert J; Quevedo G; Lobel L; Balinandi S; Lutwama JJ; Zeitlin L; Geisbert TW; Rey FA; Sidoli S; McLellan JS; Lai JR; Bornholdt ZA; Dye JM; Walker LM; Chandran K
    Cell; 2021 Jun; 184(13):3486-3501.e21. PubMed ID: 34077751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies.
    Mishra AK; Hellert J; Freitas N; Guardado-Calvo P; Haouz A; Fels JM; Maurer DP; Abelson DM; Bornholdt ZA; Walker LM; Chandran K; Cosset FL; McLellan JS; Rey FA
    Science; 2022 Jan; 375(6576):104-109. PubMed ID: 34793197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LDLR is an entry receptor for Crimean-Congo hemorrhagic fever virus.
    Xu ZS; Du WT; Wang SY; Wang MY; Yang YN; Li YH; Li ZQ; Zhao LX; Yang Y; Luo WW; Wang YY
    Cell Res; 2024 Feb; 34(2):140-150. PubMed ID: 38182887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and evaluation of neutralizing and fusion inhibitory peptides to Crimean-Congo hemorrhagic fever virus.
    Mears MC; Rodriguez SE; Schmitz KS; Padilla A; Biswas S; Cajimat MNB; Mire CE; Welch SR; Bergeron É; Alabi CA; Porotto M; Bente DA
    Antiviral Res; 2022 Nov; 207():105401. PubMed ID: 36049554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Crimean-Congo Hemorrhagic Fever Virus and Aigai Virus in Life Cycle Modeling Systems Reveals a Difference in L Protein Activity.
    Pickin MJ; Devignot S; Weber F; Groschup MH
    J Virol; 2022 Jul; 96(13):e0059922. PubMed ID: 35695578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel double-antigen sandwich ELISA for the species-independent detection of Crimean-Congo hemorrhagic fever virus-specific antibodies.
    Sas MA; Comtet L; Donnet F; Mertens M; Vatansever Z; Tordo N; Pourquier P; Groschup MH
    Antiviral Res; 2018 Mar; 151():24-26. PubMed ID: 29330092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptome profiling highlights regulated biological processes and type III interferon antiviral responses upon Crimean-Congo hemorrhagic fever virus infection.
    Mo Q; Feng K; Dai S; Wu Q; Zhang Z; Ali A; Deng F; Wang H; Ning YJ
    Virol Sin; 2023 Feb; 38(1):34-46. PubMed ID: 36075566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular (ticks) and serological (humans) study of Crimean-Congo hemorrhagic fever virus in the Iberian Peninsula, 2013-2015.
    Palomar AM; Portillo A; Santibáñez S; García-Álvarez L; Muñoz-Sanz A; Márquez FJ; Romero L; Eiros JM; Oteo JA
    Enferm Infecc Microbiol Clin; 2017; 35(6):344-347. PubMed ID: 28291670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR-/- Mice Models.
    Aligholipour Farzani T; Földes K; Hanifehnezhad A; Yener Ilce B; Bilge Dagalp S; Amirzadeh Khiabani N; Ergünay K; Alkan F; Karaoglu T; Bodur H; Ozkul A
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30857305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins.
    Bertolotti-Ciarlet A; Smith J; Strecker K; Paragas J; Altamura LA; McFalls JM; Frias-Stäheli N; García-Sastre A; Schmaljohn CS; Doms RW
    J Virol; 2005 May; 79(10):6152-61. PubMed ID: 15858000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A competitive ELISA for species-independent detection of Crimean-Congo hemorrhagic fever virus specific antibodies.
    Schuster I; Mertens M; Köllner B; Korytář T; Keller M; Hammerschmidt B; Müller T; Tordo N; Marianneau P; Mroz C; Rissmann M; Stroh E; Dähnert L; Hammerschmidt F; Ulrich RG; Groschup MH
    Antiviral Res; 2016 Oct; 134():161-166. PubMed ID: 27623345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudo-plaque reduction neutralization test (PPRNT) for the measurement of neutralizing antibodies to Crimean-Congo hemorrhagic fever virus.
    Canakoglu N; Berber E; Ertek M; Yoruk MD; Tonbak S; Bolat Y; Aktas M; Kalkan A; Ozdarendeli A
    Virol J; 2013 Jan; 10():6. PubMed ID: 23282186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.